For example, profiling of LLY-507 in multiple panels of cancer cell lines in both standard and longer duration proliferation studies revealed that 1) the catalytic function of SMYD2 plays a role not only in ESCC but in HCC and breast cancer cell proliferation and that 2) the sensitivity of tumor cell proliferation to inhibition of SMYD2 catalytic function does not depend on levels of SMYD2 expression or the methylation of either p53 or Rb. This evidence concerns the gene TP53 and esophageal squamous cell carcinoma.